{
  "schema_version": "1.0.0",
  "source": {
    "document_id": "Emerging Bronchoscopic Therapies",
    "book_title": "Principles and Practice of Interventional Pulmonology",
    "publisher": "Springer Nature Switzerland AG",
    "isbn13": "978-3-031-49583-0",
    "chapter_number": "15",
    "source_url": "https://doi.org/10.1007/978-3-031-49583-0_15",
    "file_sha256": "8e8036b43865a78ccd2e1f52b14385cc093de0d87bbe301d29d64e516bcc4d3b",
    "license": "All rights reserved",
    "rights_holder": "Springer Nature Switzerland AG",
    "access": "institutional"
  },
  "document": {
    "chapter_title": "Emerging Bronchoscopic Therapies",
    "authors": [
      "Author Name"
    ]
  },
  "structure": {
    "toc_path": [],
    "section_tree": [
      {
        "id": "sec1",
        "title": "Introduction............................................................................................... 2",
        "level": 1,
        "page_start": "?",
        "page_end": "?",
        "children": []
      },
      {
        "id": "sec2",
        "title": "TargetedLungDenervation............................................................................. 2",
        "level": 1,
        "page_start": "?",
        "page_end": "?",
        "children": [
          {
            "id": "sec2_1",
            "title": "MechanismofAction...................................................................................... 2",
            "level": 2,
            "page_start": "?",
            "page_end": "?",
            "children": []
          },
          {
            "id": "sec2_2",
            "title": "PatientSelection........................................................................................... 2",
            "level": 2,
            "page_start": "?",
            "page_end": "?",
            "children": []
          },
          {
            "id": "sec2_3",
            "title": "Procedure.................................................................................................. 2",
            "level": 2,
            "page_start": "?",
            "page_end": "?",
            "children": []
          },
          {
            "id": "sec2_4",
            "title": "EvidenceLevel............................................................................................ 4",
            "level": 2,
            "page_start": "?",
            "page_end": "?",
            "children": []
          }
        ]
      },
      {
        "id": "sec3",
        "title": "Rheoplasty................................................................................................. 4",
        "level": 1,
        "page_start": "?",
        "page_end": "?",
        "children": [
          {
            "id": "sec3_1",
            "title": "MechanismofAction...................................................................................... 4",
            "level": 2,
            "page_start": "?",
            "page_end": "?",
            "children": []
          },
          {
            "id": "sec3_2",
            "title": "PatientSelection........................................................................................... 4",
            "level": 2,
            "page_start": "?",
            "page_end": "?",
            "children": []
          },
          {
            "id": "sec3_3",
            "title": "Procedure.................................................................................................. 4",
            "level": 2,
            "page_start": "?",
            "page_end": "?",
            "children": []
          },
          {
            "id": "sec3_4",
            "title": "EvidenceLevel............................................................................................ 5",
            "level": 2,
            "page_start": "?",
            "page_end": "?",
            "children": []
          }
        ]
      },
      {
        "id": "sec4",
        "title": "SprayCryotherapy....................................................................................... 5",
        "level": 1,
        "page_start": "?",
        "page_end": "?",
        "children": [
          {
            "id": "sec4_1",
            "title": "MechanismofAction...................................................................................... 5",
            "level": 2,
            "page_start": "?",
            "page_end": "?",
            "children": []
          },
          {
            "id": "sec4_2",
            "title": "PatientSelection........................................................................................... 5",
            "level": 2,
            "page_start": "?",
            "page_end": "?",
            "children": []
          },
          {
            "id": "sec4_3",
            "title": "Procedure.................................................................................................. 5",
            "level": 2,
            "page_start": "?",
            "page_end": "?",
            "children": []
          },
          {
            "id": "sec4_4",
            "title": "EvidenceLevel............................................................................................ 6",
            "level": 2,
            "page_start": "?",
            "page_end": "?",
            "children": []
          }
        ]
      },
      {
        "id": "sec5",
        "title": "Conclusion................................................................................................ 6",
        "level": 1,
        "page_start": "?",
        "page_end": "?",
        "children": []
      }
    ]
  },
  "content": {
    "text_units": [
      {
        "id": "p1_1",
        "unit_type": "paragraph",
        "section_id": "auto",
        "order": 1,
        "text": "Emerging Bronchoscopic Therapies for Lung Disease: Targeted Lung Denervation, Rheoplasty, and Spray Cryotherapy Judith Maria Brock Contents 1 Introduction............................................................................................... 2 2 TargetedLungDenervation............................................................................. 2 2.1 MechanismofAction...................................................................................... 2 2.2 PatientSelection........................................................................................... 2 2.3 Procedure.................................................................................................. 2 2.4 EvidenceLevel............................................................................................ 4 3 Rheoplasty................................................................................................. 4 3.1 MechanismofAction...................................................................................... 4 3.2 PatientSelection........................................................................................... 4 3.3 Procedure.................................................................................................. 4 3.4 EvidenceLevel............................................................................................ 5 4 SprayCryotherapy....................................................................................... 5 4.1 MechanismofAction...................................................................................... 5 4.2 PatientSelection........................................................................................... 5 4.3 Procedure.................................................................................................. 5 4.4 EvidenceLevel............................................................................................ 6 5 Conclusion................................................................................................ 6 References....................................................................................................... 7 Abstract spray cryotherapy induces fresh-freezing of the goblet cells by delivering a precise thermal dose of liquid nitroChronic obstructivepulmonary diseasepresentswithdifgenat-196°Ctothelung.Bothproceduresaimtoreduce ferentphenotypes.Whilepatientswithpulmonaryemphysema and hyperinflation are treated with lung volume goblet cell hyperplasia and thereby sputum overproduction and improve quality of life. These innovative reduction therapies, new treatment options are available new treatment options are still under investigation but for patients suffering mainly from chronic bronchitis and have shown promising results in recent trials in patients COPD exacerbations. Targeted lung denervation aims to ablate the parasympathetic fibers ofthe vagus nerve with withpersistentsymptomsdespiteoptimalmedicaltherapy. Careful patient selection is key to successful therapy. radiofrequency energy, in order to reduce bronchoconFurther studies are needed before implementation of striction and exacerbations. Bronchial rheoplasty and thesetherapiesinroutineclinicalpractice. spray cryotherapy both target patients with symptoms of chronic bronchitis. While bronchial rheoplasty uses nonKeywords thermal,pulsedelectricalenergytoablatethegobletcells, ✉ Bronchialrheoplasty·Spraycryotherapy·Metered J.M.Brock( ) cryospray·Targetedlungdenervation·Chronic ThoraxklinikHeidelberg,UniversityofHeidelberg,Translational ResearchCenterHeidelberg(TLRC),GermanCenterforLungResearch bronchitis·COPD·COPDexacerbation (DZL),Heidelberg,Germany e-mail:Judith.Brock@med.uni-heidelberg ©SpringerNatureSwitzerlandAG2025 1 L.Yarmusetal.(eds.),PrinciplesandPracticeofInterventionalPulmonology, https://doi.org/10.1007/978-3-031-49583-0_56-1",
        "tokens": 283,
        "page_range": [
          "1"
        ],
        "provenance": {
          "page": "1",
          "paragraph_index": 1
        }
      },
      {
        "id": "p2_1",
        "unit_type": "paragraph",
        "section_id": "auto",
        "order": 1,
        "text": "2 J.M.Brock 1 Introduction lung (Fig. 2). The aim is to reduce bronchoconstriction, inflammation, and exacerbations. A small pilot study Chronic obstructive pulmonary disease (COPD) is a disease suggested further effects of TLD on airway remodeling and with many faces. Inaddition tothewell-knownemphysema airwayinflammation,measuredbycytokineanalysesinbronphenotype,thereareotherphenotypes.Muchefforthasbeen chialwashandbrush[3]. madetocharacterizeanddifferentiatethemanyaspectsofthe disease. Some patients suffer mainly from multiple exacerbations 2.2 Patient Selection of COPD, mainly caused by viral and bacterial infections. Increased vagal reflex signaling and subsequent parasympa- Patients with at least two moderate exacerbations in the last thetic overstimulation are thought to influence exacerbation 12 months, requiring antibiotic or corticosteroid treatment, frequency, airway inflammation, and mucus hypersecretion. arepossiblecandidatesforthistreatment.Bothpatientswith Forthisreason,pharmacologicalblockadeoftheparasympa- thechronicbronchitisphenotypeandemphysemaphenotype theticairwaysystem(long-actingmuscarinicantagonists)isa that are under optimal medical treatment are addressed. well-establishedtherapeuticapproachforCOPD[1]. Patients with bacterial-driven exacerbations that are due to Exacerbations lead to a progressive loss of lung function persistentcolonizationwithpathogenicbacteriaorsignificant andincreasetheriskofcardiovascularevents.Manypatients gastrointestinalcomorbiditiesshouldnotundergoTLD.Curexperience high rates of exacerbations despite optimal med- rently,patientswithadiagnosisofasthmaareexcludedfrom ical management. Preventing exacerbations is therefore a treatment. A prior CT (computed tomography) scan is primary goal of COPD therapy. Targeted lung denervation performed to check whether the bronchial anatomy allows has been developed to reduce the sympathetic over- treatment with the available catheter sizes and to exclude stimulationinadditiontopharmacologicaltherapy. patients with severe emphysema (>50% emphysema index Chronic bronchitis is defined as cough and sputum pro- atHounsefieldUnits—950). ductionforatleast3monthsinatleast2years.Thisphenotype of COPD is described as obese and less symptomatic, butinfact,manypatientssufferfromchronicbronchitisand 2.3 Procedure experience a rapid decline in lung function, reduced quality of life, and repeated hospitalizations. Chronic bronchitis is Therapy is administered during one bronchoscopy session thoughttoresultfromanincreaseinthenumberandsize of under general anesthesia. The Lung Denervation System of goblet cells in the bronchial mucosa. Parasympathetic over- Nuvaira (Minnesota, USA), which received a CE mark in stimulation exacerbates symptoms by causing bronchocon- Europe in 2016, consists of a dual-cooled radiofrequency striction and inflammation. Treatment strategies have (RFA) catheter (Fig. 3) and aconsole. Aperistaltic pump in thereforebeendevelopedtotargetthisgobletcellhyperplasia the generator cools and circulates the coolant fluid through using either electrical current (bronchial rheoplasty) or cold the catheter into the balloon at the tip of the catheter to (spraycryotherapy)[2]. minimize damage to the bronchi. The catheter is available Taken together, these new bronchoscopic therapies in different sizes, dependent on the diameter of the main expand the landscape of bronchoscopic COPD therapy bronchi, and the energy level is chosen dependent on the alongside lung volume reduction therapies in patients with individual anatomy (26–32 watts). The catheter is inserted emphysema. A detailed baseline assessment and evaluation through the bronchoscope and placed in both main bronchi of thedifferent phenotypes isnecessary as a precriterionfor circumferentially to ablate the vagal fibers at four different theselectionofthespecifictherapyoption(Fig.1). positions. Recently, a balloon catheter, filled with contrast, has been introduced into the esophagus prior to the procedure, and care is taken to maintain an appropriate distance 2 Targeted Lung Denervation betweentheelectrodeandtheesophagus,toavoidablationof gastric vagal fibers and to prevent gastrointestinal side TargetedlungdenervationaddressespatientswithCOPDand effects. The main challenge of the procedure is the correct frequentexacerbations. positioning of the ablation catheter. Currently, radiofrequency ablation requires 120 s of activation and 30 s of postcooling. Prophylactic antibiotic and cortisone treatment 2.1 Mechanism of Action isgiven.Thecompleteprocedurelastsabout74min[4].Possible side effects include COPD exacerbation, pulmonary Targetedlungdenervation(TLD)usesradiofrequencyenergy infection,damagetotheairwaymucosa,andgastrointestinal toablatetheparasympatheticfibersofthevagusnerveinthe sideeffects.",
        "tokens": 668,
        "page_range": [
          "2"
        ],
        "provenance": {
          "page": "2",
          "paragraph_index": 1
        }
      },
      {
        "id": "p3_1",
        "unit_type": "paragraph",
        "section_id": "auto",
        "order": 1,
        "text": "EmergingBronchoscopicTherapiesforLungDisease:TargetedLungDenervation,Rheoplasty,andSpray… 3 Fig.1 Patientselectionfor bronchoscopictherapiesfor COPD and/or COPDandchronicbronchitis ChronicBronchitis Symptomaticdespite optimizedmedication and conservativetherapy Screening, phenotype Emphysema other phenotype ChronicBronchitis Lung volume Rheoplasty/ Cryospray reduction CAT first2 questions≥ 7 endoscopicorsurgical Exacerbations TargetedLung Denervation ≥ 2 moderate COPD exacerbationsin last 12 months Fig.2 MechanismofactionofanticholinergicdrugsandtargetedlungdenervationinCOPD.(CourtesyofNuvaira,Inc.Minneapolis,MN,USA)",
        "tokens": 54,
        "page_range": [
          "3"
        ],
        "provenance": {
          "page": "3",
          "paragraph_index": 1
        }
      },
      {
        "id": "p4_1",
        "unit_type": "paragraph",
        "section_id": "auto",
        "order": 1,
        "text": "4 J.M.Brock Fig.3 dNerva™DualCooled RadiofrequencyCatheterfor targetedlungdenervation. (CourtesyofNuvaira,Inc. Minneapolis,MNUSA) 2.4 Evidence Level Pre- and postreatment analyses of endobronchial cryobiopsies showed a reduction of goblet cell hyperplasia Followingnumerousanimalandhumancadaverstudies,the score (ratio of goblet cells to ciliated bronchial epithelial firstfeasibilityandsafetystudieswereconductedinhumans. cells)[8]. Theprocedurewastechnicallyfeasiblein93%.Theoptimal energydoseforsufficientefficacywastestedandprocedural adjustmentsweremadetobetterprotecttheairwaywalland 3.2 Patient Selection theesophagus.Theprocedureevolvedfromatwo-stagetoa single-stageprocedure.Asecondgenerationdevicewaslater Patients with a high symptom burden due to chronic bronused and tested, in two different doses, in a randomized- chitis are considered for this treatment. This inclusion is controlledtrialwithfurtherproceduraladjustments(Airflow challenged by the fact that an objective measure of sputum 1 study) [5]. As a result of gastrointestinal side effects, an volumeandsputumdiseaseburdenisdifficulttofind.Inthe esophageal balloon was added to ensure sufficient distance absence of other objective criteria, the CAT (COPD assessbetween the esophagus and the electrode and thus prevent menttest)questionnairewaschosenastheleadingindication unintentional treatment of the gastric parasympathetic plexi. for this therapy, with the first two questions on sputum and Follow-up data are now available up to 3 years and showed cough ≥7 and the complete score ≥10 leading to entry into an acceptable safety profile. The Airflow 2 study [6, 7] this treatment option. Patients with cardiac arrhythmias or (results of the treatment and crossover group) could then implantableelectronicdevicescannotbetreated,becausethe demonstrateareductioninexacerbationsaswellasaprolon- application of the activations is timed to the actual heart gation of time to first exacerbation over 2 years. Technical rhythmandamonopolarelectrodeisused.Currently,further success of radiofrequency application was 90%. Lung func- exclusioncriteriaarethepresenceofpulmonaryemphysema tionandqualityofliferemainedstable,whichisencouraging (emphysema index >25% at -950 Hounsefield Units), a giventheprogressivenatureofthedisease.Theresultsofthe diagnosisofasthmabronchiale,oraknownairwaycolonizaAirflow3studyareawaitedtoconfirmtheseresultsandwill tionwithresistantorganismssuchaspseudomonas. helptodecideonthefurtherimplementationofthistreatment optionindailypractice. 3.3 Procedure The system includes an electrosurgical generator and a 3 Rheoplasty single-usecatheterthatisinsertedthroughthebronchoscope (Fig. 4). Bronchial rheoplasty is performed under general Bronchial rheoplasty is aimed specifically at patients with anesthesia in two sessions, one on the right side and chronicbronchitistoreducesputumburdenandsymptoms. 4–6 weeks apart on the left side. A neutral electrode is attached to the patient prior to the procedure. With FiO2 reduced to 30%, the catheter is deployed stepwise in all 3.1 Mechanism of Action segments from the distal subsegmental bronchi up to the maincarina.Theelectrodeisexpandedtocoverthebronchial Bronchial rheoplasty uses nonthermal, high-frequency mucosa, and then electric current is applied over 5 s by pulsed electrical energy to ablate the goblet cells of the steppingonafootpedal.Afterthat,theelectrodeiscollapsed bronchial mucosa. Cell death is induced by a disruption of andmovedtothenextarea(Fig.5).Theaveragedurationof the cellular homeostasis, osmotic swelling, and apoptosis. theprocedureis40minwith40–60activationsperlungside. The extracellular matrix remains intact, allowing the epithe- Corticosteroids are applied to prevent COPD exacerbation, liumtoregenerateandnewgobletcellstogrow,butinnormal which is the main side effect of the procedure apart from size and number. This helps to reduce sputum pneumonia. overproduction.",
        "tokens": 523,
        "page_range": [
          "4"
        ],
        "provenance": {
          "page": "4",
          "paragraph_index": 1
        }
      },
      {
        "id": "p5_1",
        "unit_type": "paragraph",
        "section_id": "auto",
        "order": 1,
        "text": "EmergingBronchoscopicTherapiesforLungDisease:TargetedLungDenervation,Rheoplasty,andSpray… 5 Fig.4 Rheoplastycatheter.(CourtesyofGalvanizeTherapeutics,Inc., RedwoodCity,USA) 3.4 Evidence Level This therapy approach is still under investigation, with a Fig.5 Rheoplastycatheterintheleftupperlobe.(CourtesyofJudith growing body of real-world data, but no randomized trial Brock,Heidelberg,Germany) resultstodate. Valipour et al. demonstrated the feasibility and safety of 4.1 Mechanism of Action the procedure in two pooled multicenter clinical trials, treating 30 patients with chronic bronchitis. The most com- A precise thermal dose of liquid nitrogen (“metered mon adverse event was COPD exacerbation. Symptom cryospray”)at-196°Cisdeliveredtotargetedareaswithin scores of SGRQ (St. George’s Respiratory Questionnaire) thelung.Theflash-freezingdisruptsthecellularstructuresof andCATwerereducedat6and12months[8].Theseresults thegobletcellswithoutdamagingtheextracellularmatrix.It werereproducedinamulticenterstudyinwhich21patients hasbeenshowninpilotstudiestobelimited tothemucosal were treated and followed up for 2 years, with COPD exac- andsubmucosallayerswithoutdamagingthecartilagelevel. erbation and pneumonia being the most common serious Overtime,newhealthycellsand“healthy”mucus-producing adverse events. Overall, there was a trend for the effects to gobletcellsrepopulate. diminish over time (12 months, 24 months). Moreover, a reduction in the rate of exacerbations has been reported [9].Thereare unanswered questions about thepossibility of 4.2 Patient Selection retreatmentintheeventofrecurrenceofsymptomsorpatient selection, including the treatment of patients with emphy- PatientswithadiagnosisofchronicbronchitisandCOPDfor sema and chronic bronchitis who were previously excluded atleast2yearsareeligibleforthistreatment.Currentexclufromtreatment. sion criteria are a diagnosis of asthma bronchiale or Severalstudiesareunderwayorhavebeencompletedbut bronchiectasis. resultsarepending,includingarandomizedsham-controlled trial. Unfortunately, the manufacturer has focused its efforts on this treatment option for the US market, so bronchial 4.3 Procedure rheoplasty is currently only available in the US and not in theEuropeanUnion. Indetail,adeliverycatheter(Fig.6)whichcollectsnitrogen fromaconsoleisinsertedoverthebronchoscopeandapplies liquidnitrogenasaradialspraytothebronchialairwaysfrom 4 Spray Cryotherapy thedistalbronchiuptothemaincarina(Fig.7).Theamount ofliquidnitrogen deliveredisbased ontheairwaysizewith Spray cryotherapy has been developed for patients with theaimofcreatinga10mmcircularcryoablationzonewitha chronic bronchitis who suffer from cough and increased depthof0.1–0.5mm.Thisisachievedbyreal-timefeedback sputumproduction.Theaimistoablateabnormalepithelium tothethermocoupleonthedeliverycatheter.Ventilationmust andfacilitatetheformationofhealthymucosa. bestoppedduringapplicationandthecuffoftheendotracheal tube is usually deflated to avoid barotrauma or asphyxia. Threeproceduresarerequired,withtherightlowerlobeand mainstembronchustreatedinthefirstsession,theleftlower",
        "tokens": 331,
        "page_range": [
          "5"
        ],
        "provenance": {
          "page": "5",
          "paragraph_index": 1
        }
      },
      {
        "id": "p6_1",
        "unit_type": "paragraph",
        "section_id": "auto",
        "order": 1,
        "text": "6 J.M.Brock lobeandmainstembronchusinthesecondsession,andboth events were reported [11]. In 2017, two pilot studies of the upper lobes and the distal end of the trachea in the third RejuvenAir®systemwith16non-CBparticipantsalsodemsession. The right middle lobe is not treated because of the onstrated the feasibility and safety of spray cryotherapy. expected higher risk ofbarotraumain a small structure. The Onceagain,itwasshownthatthecartilage wasnotaffected meannumberofspraydeliveriesperprocedurewasreported and that the treatment effect extended to the submucosal tobe20andthemeanproceduretimewas34min[10]. level[12]. TheRejuvenAir®System(CSAMedical,Lexington,MA, USA) has received CE mark in Europe and breakthrough device designation and investigational device exemption 4.4 Evidence Level (IDE)fromtheUSFoodandDrugAdministration(FDA)in 2019. A multicenter, prospective, single-arm study in the This treatment approach is still under investigation. Spray UnitedKingdom,theNetherlands,andCanadademonstrated cryotherapy with liquid nitrogen was already performed in feasibility,anacceptablesafetyprofileandeffectivesymptom 2010on21non-CBsubjectspriortolobectomy,atthattime reduction in 35 patients with chronic bronchitis. Endousing the cryoSpray Ablation System (CSA Medical, Inc., bronchial biopsies showed no clear histological differences, Baltimore,Md).Low-pressureliquidnitrogenwasappliedto but there was a visually assessed reduction in mucus. No the airways. The treated airways showed cryonecrosis, limpneumothoraxoccurredasresultofpotentialbarotraumaand ited to the mucosal and submucosal layers, and no adverse themainadverseeventswereCOPDexacerbationandpneumonia. Patients experienced benefits in symptom scores (SGRQ, CAT, Leicester Cough Questionnaire) at 3 months withlonger-termeffectsupto6–9months[10]. Theresultsoftwoactive,nonrecruitingstudies,oneinvestigating the mechanism of action and the other a shamcontrolledprospectiverandomizedclinicaltrial,areexpected to confirm these initial promising results with feasibility, acceptable safety, and the potential to effectively reduce symptomsinCBpatients[13,14]. 5 Conclusion Bronchoscopic treatment options for COPD are emerging and offer differentiated therapies for specific phenotypes. Fig. 6 RejuvenAir Cryospray catheter. (Courtesy of CSA Medical, Inc.,Lexington,MA) However, the heterogeneous patient cohort requires Fig.7 Meteredcryospraytherapy.(CourtesyofDJSlebos,Groningen,Netherlands)",
        "tokens": 314,
        "page_range": [
          "6"
        ],
        "provenance": {
          "page": "6",
          "paragraph_index": 1
        }
      },
      {
        "id": "p7_1",
        "unit_type": "paragraph",
        "section_id": "auto",
        "order": 1,
        "text": "EmergingBronchoscopicTherapiesforLungDisease:TargetedLungDenervation,Rheoplasty,andSpray… 7 appropriate patient selection, and the provision of reliable moderate to severe chronic obstructive pulmonary disease: study results for implementation in daily clinical practice. AIRFLOW-2. Respiration. 2022;101:1069–74. https://doi.org/10. 1159/000527455. Future studies will have to show whether a combination of 7.ValipourA,ShahPL,HerthFJ,PisonC,SchumannC,HübnerR-H, thedifferentbronchoscopictherapiesispossibleornecessary etal.Two-yearoutcomesforthedouble-blind,randomized,shamfor mixed phenotypes. In addition, new options often lack controlledstudyoftargetedlungdenervationinpatientswithmodfinancialreimbursementandmaythereforefacechallengesto eratetosevereCOPD:AIRFLOW-2.IntJChronObstructPulmon Dis.2020;15:2807–16.https://doi.org/10.2147/COPD.S267409. beimplementedindailypracticeinallcountries.Itremainsto 8.Valipour A, Fernandez-Bussy S, Ing AJ, Steinfort DP, Snell GI, be hoped that these promising therapies will find their way WilliamsonJP,etal.Bronchialrheoplastyfortreatmentofchronic into clinical practice, help COPD patients ina differentiated bronchitis. Twelve-month results from a multicenter clinical trial. way, and leave room for us to learn more about COPD Am J Respir Crit Care Med. 2020;202:681–9. https://doi.org/10. 1164/rccm.201908-1546OC. phenotypesfrombedsidetobench. 9.Sciurba FC, Dransfield MT, Kim V, Marchetti N, Comellas A, HogarthDK,MajidA.Bronchialrheoplastyforchronicbronchitis: 2-yearresultsfromaUSfeasibilitystudywithRheOx.BMJOpen References Respir Res. 2023;10:e001710. https://doi.org/10.1136/bmjresp2023-001710. 1.BelmonteKE.Cholinergicpathwaysinthelungsandanticholiner- 10.Garner JL, Shaipanich T, Hartman JE, Orton CM, Caneja C, gic therapy for chronic obstructive pulmonary disease. Proc Am Klooster K, et al. A prospective safety and feasibility study of ThoracSoc.2005;2:297–304;discussion311–2.https://doi.org/10. metered cryospray for patients with chronic bronchitis in COPD. 1513/pats.200504-043SR. Eur RespirJ.2020;56:2000556. https://doi.org/10.1183/13993003. 2.GlobalInitiativeforChronicObstructiveLungDisease,Inc.Global 00556-2020. strategyforthediagnosis,management,andpreventionofCOPD: 11.KrimskyWS,BroussardJN,SarkarSA,HarleyDP.Bronchoscopic 2024report.2025.https://goldcopd.org/2024-gold-report/ spraycryotherapy:assessmentofsafetyanddepthofairwayinjury.J 3.Kistemaker LEM, Slebos D-J, Meurs H, Kerstjens HAM, Gosens ThoracCardiovascSurg.2010;139:781–2.https://doi.org/10.1016/j. R.Anti-inflammatoryeffectsoftargetedlungdenervationinpatients jtcvs.2009.03.051. with COPD. Eur Respir J. 2015;46:1489–92. https://doi.org/10. 12.SlebosD-J,BreenD,CoadJ,KloosterK,HartmanJ,BrowningR, 1183/13993003.00413-2015. etal.Safetyandhistologicaleffectofliquidnitrogenmeteredspray 4.Slebos D-J, Shah PL, Herth FJF, Pison C, Schumann C, Hübner cryotherapy in the lung. Am J Respir Crit Care Med. 2017;196: R-H,etal.Safetyandadverseeventsaftertargetedlungdenervation 1351–2.https://doi.org/10.1164/rccm.201611-2220LE. forsymptomaticmoderatetoseverechronicobstructivepulmonary 13.MayrAK,ValipourA.ModernBronchoscopictreatmentoptionsfor disease(AIRFLOW).Amulticenterrandomizedcontrolledclinical patientswithchronicbronchitis.JClinMed.2023.https://doi.org/ trial. Am J Respir Crit Care Med. 2019;200:1477–86. https://doi. 10.3390/jcm12051854. org/10.1164/rccm.201903-0624OC. 14.HartmanJE,GarnerJL,ShahPL,SlebosD-J.Newbronchoscopic 5.ValipourA,ShahPL,PisonC,NinaneV,JanssensW,PerezT,etal. treatmentmodalitiesforpatientswithchronicbronchitis.EurRespir Safety and dose study of targeted lung denervation in moderate/ Rev. 2021;30:200281. https://doi.org/10.1183/16000617. severe COPD patients. Respiration. 2019;98:329–39. https://doi. 0281-2020. org/10.1159/000500463. 6.ConwayF,TonkinJ,ValipourA,PisonC,SchumannC,BontaPI, et al. Crossover patient outcomes for targeted lung denervation in",
        "tokens": 360,
        "page_range": [
          "7"
        ],
        "provenance": {
          "page": "7",
          "paragraph_index": 1
        }
      }
    ],
    "figures": [
      {
        "id": "fig_3_1",
        "number": "1",
        "page": "3",
        "provenance": {
          "page": "3",
          "label": "Fig 1"
        }
      },
      {
        "id": "fig_3_2",
        "number": "2",
        "page": "3",
        "provenance": {
          "page": "3",
          "label": "Fig 2"
        }
      },
      {
        "id": "fig_4_3",
        "number": "3",
        "page": "4",
        "provenance": {
          "page": "4",
          "label": "Fig 3"
        }
      },
      {
        "id": "fig_5_4",
        "number": "4",
        "page": "5",
        "provenance": {
          "page": "5",
          "label": "Fig 4"
        }
      },
      {
        "id": "fig_5_5",
        "number": "5",
        "page": "5",
        "provenance": {
          "page": "5",
          "label": "Fig 5"
        }
      },
      {
        "id": "fig_6_6",
        "number": "6",
        "page": "6",
        "provenance": {
          "page": "6",
          "label": "Fig 6"
        }
      },
      {
        "id": "fig_6_7",
        "number": "7",
        "page": "6",
        "provenance": {
          "page": "6",
          "label": "Fig 7"
        }
      }
    ],
    "tables": [],
    "boxes": [],
    "equations": [],
    "cases": [],
    "references": []
  },
  "retrieval": {
    "keywords": [],
    "summary_tldr": "Auto-built chapter JSON for Emerging Bronchoscopic Therapies.",
    "nuggets": [],
    "chunks": []
  },
  "versioning": {
    "extraction_tool": "build_chapter.py",
    "model": "none",
    "timestamp": "2025-08-08T16:01:07.896496Z",
    "revision": "r1"
  }
}